Differentiating Persistent Sepsis From Pembrolizumab-Induced Secondary Hemophagocytic Lymphohistiocytosis and Concurrent Immune-Mediated Nephritis: A Diagnostic and Therapeutic Challenge
Ahmed Nisar · 2026
Read Differentiating Persistent Sepsis From Pembrolizumab-Induced Secondary Hemophagocytic Lymphohistiocytosis and Concurrent Immune-Mediated Nephritis: A Diagnostic and Therapeutic Challenge by Ahmed Nisar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13634666.txt.
Description
Ahmed Nisar reports a case in which a cancer drug's rare inflammatory complication masqueraded as stubborn infection, in a paper published in two thousand twenty-six. The patient was a thirty-nine-year-old woman with triple-negative breast cancer, treated with chemotherapy plus pembrolizumab, an immune checkpoint inhibitor.
Two weeks after her last cycle she arrived with fever, a widespread rash, and discharge from a catheter site. Blood cultures first grew Gram-positive bacteria, pointing to sepsis. Even after the microbes cleared under broad antibiotics, her picture fit hemophagocytic lymphohistiocytosis, a dangerous over-inflammatory syndrome the immunotherapy can trigger. Kidney inflammation from the same immune activation appeared alongside. Telling sepsis apart from drug-induced HLH is hard because the two share fever, rash, and crashing labs. The case walks through the diagnostic and treatment reasoning. It warns oncologists to suspect the drug when infection treatment stalls.
Catalog record
| CREATOR | Ahmed Nisar |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |